SCPH Company Profile and Key Details

Short-term trend indicators are bearishly aligned (SMA20 0.57%, SMA50 6.1%, SMA200 46.89%). The stock’s 14-day RSI is 64.4 (firm momentum), while the ATR of 0.07 points to moderate volatility. The stock remains hovering near 52-week lows, trading -9.71% below its high and over 192.27% above its low.

scPharmaceuticals Inc. generated EPS of -$1.81 over the past year. Five-year average earnings growth is -1.52%. The latest quarter delivered EPS of -$0.37. The next quarter is forecast at -$0.24. Next year's EPS is expected at $21.39. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 2 Buy ratings, 1 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $18.00 to $6.00. The high target offers 217.46% upside. The low target suggests 5.82% downside. The mean target is $12.00. This offers 111.64% upside. scPharmaceuticals Inc. earnings surprise history is a consistent trend of beating forecasts. The quarter that ended November 12, 2025, missed forecasts by 48.0%. The prior quarter beat by 13.33%. Over the last six quarters, Apple has recorded several small beats. These include 4.38% in August 14, 2024.

scPharmaceuticals Inc. has 53.30 million shares outstanding. The public float is 32.54 million shares, elevated short interest at 2.18% of float. This equals 1.01 million shares. The short ratio is 3.26 days. Institutional investors hold 80.54% of the float. Insiders own 5.98%. RA CAPITAL MANAGEMENT, LLC holds 3.25 million shares, Lundbeckfond Invest A/S has 3.18 million shares and Agger Mette Kirstine has 3.18 million shares.

scPharmaceuticals Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $9.83. This means the shares are trading below this model’s fair value.

The stock is currently mid-range between its 52-week high and low $1.94 and $6.28. With a market capitalization of about $302.20 million, scPharmaceuticals Inc. is classified as a small-cap and shows lower-than-market volatility (beta ~0.30). Key stats such as the average daily volume over the past year has been around 1.45 million shares, trading with heavier-than-usual volume. Headquartered in Burlington, MA, scPharmaceuticals Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO John H. Tucker, the company employs approximately 162 people and listed since November 17, 2017. scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products.

Our AI price prediction model suggests that scPharmaceuticals Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 1.76%, with price expected at $5.77 by October 20, 2025, within a range of $5.58 to $5.97 3-Month Outlook: Projected rise of 67.02%, reaching $9.47 by January 02, 2026, with a range of $9.23 to $9.81. 1-Year Outlook: Projected gain of 445.15%, with price at $30.91 by October 06, 2026, within a range of $25.03 to $42.75.

scPharmaceuticals Inc. (NASDAQ:SCPH) shares are up 60.17% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows scPharmaceuticals Inc. trading at a premium to the broader market with a P/E of -3.32. Analyst sentiment is mixed, with the majority of ratings in Hold territory and a mean price target of $15.73, suggesting 177.43% upside. Our AI forecast model points to short-term strength (1.76% over two weeks), a medium-term rise (67.02% over three months), and a longer-term gain (445.15% over one year), with expected trading ranges indicating moderate volatility.

scPharmaceuticals Inc. trades at a P/E ratio of -3.32, slightly below the S&P 500 average, with a price-to-sales ratio of 6.05 and a price-to-book ratio of -14.29 indicating negative book value, which may reflect financial stress. The P/FCF stands at -4.59, also below market averages.